David Wang
Direttore/Membro del Consiglio presso BIOVAXYS TECHNOLOGY CORP.
Patrimonio netto: 92 540 $ in data 30/04/2024
Profilo
David Wang is currently the Chief Executive Officer at Encounter Technology Ltd., Director at BioVaxys Technology Corp., and Director at BioVaxys LLC.
Previously, he worked as the Chief Executive Officer at Beijing Century Medical.
Mr. Wang holds an MBA from the University of International Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
BIOVAXYS TECHNOLOGY CORP
1.03% | 08/02/2023 | 1 492 575 ( 1.03% ) | 92 540 $ | 30/04/2024 |
Posizioni attive di David Wang
| Società | Posizione | Inizio |
|---|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Direttore/Membro del Consiglio | - |
BioVaxys LLC
 BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Direttore/Membro del Consiglio | - |
| Encounter Technology Ltd. | Amministratore Delegato | - |
Precedenti posizioni note di David Wang
| Società | Posizione | Fine |
|---|---|---|
| Beijing Century Medical | Amministratore Delegato | - |
Formazione di David Wang
| University of International Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Non-Energy Minerals |
| Aziende private | 3 |
|---|---|
| Beijing Century Medical | |
BioVaxys LLC
BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Health Technology |
| Encounter Technology Ltd. |
- Borsa valori
- Insiders
- David Wang